GSK to file for approval of twice-yearly hep B drug on positive Phase III data
GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.
08 January 2026
08 January 2026
GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.